SEATTLE, Sept. 9, 2012 /PRNewswire/ --The Heart Failure Society of America (HFSA) 16th Annual Scientific Meeting convened today at the Washington State Convention Center in Seattle. The meeting will feature several satellite sessions this afternoon and tomorrow, which are sponsored by educational grants from several outside supporters of HFSA.
This year's satellite symposia feature several interesting topics, including:
- The Tao of the Right Ventricle: A Wicked Problem
- Mechanically Assisted Circulation: Therapeutic Options Across the Spectrum of Advanced Heart Failure
- The Impact of New Rhythm Device Technology on Patient Management Options
- Achieving Treatment Success for Patients with Heart Failure Complicated by Hyponatremia
- Sleep Disordered Breathing in Heart Failure: Challenges and Opportunities
- Hydralazine and Isosorbide Dinitrate Therapy in Heart Failure: Past, Present and Future
The 16th Annual Scientific Meeting is a four-day forum for heart failure specialists to present research findings and advances in treatment. Presentations will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.
For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7193 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may follow news from the meeting on Twitter @HFSA and #HFSA
About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.
About the Heart Failure Society of America
The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.
SOURCE Heart Failure Society of America
